Bleakley Financial Group LLC Reduces Stock Position in Takeda Pharmaceutical Company Limited (NYSE:TAK)

Bleakley Financial Group LLC lowered its holdings in shares of Takeda Pharmaceutical Company Limited (NYSE:TAK) by 5.0% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 318,340 shares of the company’s stock after selling 16,830 shares during the quarter. Bleakley Financial Group LLC’s holdings in Takeda Pharmaceutical were worth $4,215,000 as of its most recent SEC filing.

A number of other large investors also recently bought and sold shares of the business. Five Oceans Advisors boosted its holdings in Takeda Pharmaceutical by 22.2% during the 4th quarter. Five Oceans Advisors now owns 18,502 shares of the company’s stock valued at $245,000 after acquiring an additional 3,364 shares during the period. SYM FINANCIAL Corp purchased a new position in Takeda Pharmaceutical during the 4th quarter valued at $140,000. First Affirmative Financial Network raised its position in Takeda Pharmaceutical by 29.8% during the 4th quarter. First Affirmative Financial Network now owns 20,602 shares of the company’s stock valued at $273,000 after purchasing an additional 4,736 shares in the last quarter. Highland Capital Management LLC raised its position in Takeda Pharmaceutical by 9.8% during the 4th quarter. Highland Capital Management LLC now owns 67,700 shares of the company’s stock valued at $896,000 after purchasing an additional 6,050 shares in the last quarter. Finally, Blue Trust Inc. raised its position in Takeda Pharmaceutical by 27.0% during the 4th quarter. Blue Trust Inc. now owns 14,430 shares of the company’s stock valued at $205,000 after purchasing an additional 3,071 shares in the last quarter. Hedge funds and other institutional investors own 9.17% of the company’s stock.

Takeda Pharmaceutical Trading Up 1.7 %

Shares of NYSE TAK opened at $13.60 on Friday. The company has a quick ratio of 0.72, a current ratio of 1.31 and a debt-to-equity ratio of 0.63. The business has a fifty day simple moving average of $13.30 and a two-hundred day simple moving average of $13.88. The firm has a market cap of $43.26 billion, a PE ratio of 33.99, a price-to-earnings-growth ratio of 0.23 and a beta of 0.51. Takeda Pharmaceutical Company Limited has a twelve month low of $12.57 and a twelve month high of $15.08.

Takeda Pharmaceutical (NYSE:TAK) last issued its earnings results on Thursday, January 30th. The company reported $0.42 earnings per share for the quarter, beating analysts’ consensus estimates of $0.34 by $0.08. Takeda Pharmaceutical had a return on equity of 9.39% and a net margin of 4.53%. Analysts expect that Takeda Pharmaceutical Company Limited will post 1.64 earnings per share for the current fiscal year.

Takeda Pharmaceutical Profile

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.